Table 1.
Gender | On therapy | CD4 cells/μL of blood | HIV RNA copies/mL |
HIV RNA copies/mL |
Next-generation sequences generated |
SGA sequences generated |
CM antigen in CSF | CM confirmation method | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Plasma | CSF | Plasma | CSF | Plasma | CSF | ||||||
A02 | Male | Yes | 311 | 27,456 | 3,656 | 47 | 55 | 29 | 26 | No | CrAg test |
A03 | Female | Yes | 251 | 320 | 320 | — | — | — | — | No | CrAg test |
A04 | Female | Yes | 51 | 162,544 | 2,104 | 33 | 120 | 24 | 15 | No | CrAg test |
A05 | Female | Yes | 125 | 5,648 | 4,608 | 33 | 327 | 2 | 22 | No | CrAg test |
A06 | Female | Yes | 355 | 320 | 320 | — | — | — | — | No | CrAg test |
A07 | Male | Yes | 245 | 320 | 320 | — | — | — | — | No | CrAg test |
A08 | Male | No | NA | 3,235,600 | 720 | 779 | 0 | — | — | No | CrAg test |
A09 | Female | Yes | 84 | 320 | 320 | — | — | — | — | No | CrAg test |
A10 | Female | Yes | 349 | 439,512 | 554,088 | 883 | 2,320 | 19 | 41 | No | CrAg test |
A11 | Female | Yes | 406 | 320 | 320 | — | — | — | — | No | CrAg test |
A13 | Male | Yes | 130 | 1,073,000 | 5,107,488 | 334 | 35,114 | 38 | 36 | No | CrAg test |
A01 | Male | Yes | 17 | 122,088 | 320 | 110 | — | — | — | Yes | CrAg test |
A12 | Male | Yes | 16 | 11,480 | 6,344 | 192 | 969 | 6 | 18 | Yes | CrAg test |
ACTA3153 | Female | Yes | 9 | 10,048 | 1,368 | — | — | ND | ND | Yes | Culture |
ACTA3154 | Male | Yes | 9 | 320 | 320 | — | — | ND | ND | Yes | Culture |
ACTA3155 | Male | Yes | 294 | 320 | 320 | — | — | ND | ND | Yes | Culture |
ACTA3156 | Female | No | 32 | 35,528 | 320 | — | — | ND | ND | Yes | Culture |
ACTA3157 | Male | No | 15 | 94,392 | 320 | — | — | ND | ND | Yes | Culture |
ACTA3159 | Male | No | 43 | 680,442 | 14,640 | 905 | — | ND | ND | Yes | Culture |
ACTA3160 | Male | Yes | 5 | 7,976 | 320 | — | — | ND | ND | Yes | Culture |
ACTA3162 | Male | Yes | 35 | 70,408 | 320 | 97 | — | ND | ND | Yes | Culture |
ACTA3163 | Female | No | 18 | 157,120 | 320 | 41 | — | ND | ND | Yes | Culture |
ACTA3164 | Male | Yes | 26 | 320 | 1,328 | — | — | ND | ND | Yes | Culture |
ACTA3165 | Female | Yes | 3 | 20,616 | 320 | 4 | — | ND | ND | Yes | Culture |
ACTA3166 | Female | No | 7 | 181,920 | 1,008 | 75 | — | ND | ND | Yes | Culture |
ACTA3167 | Male | Yes | 65 | 320 | 320 | — | — | ND | ND | Yes | Culture |
ACTA3168 | Female | Yes | 121 | 320 | 520 | — | — | ND | ND | Yes | Culture |
ACTA3169 | Female | Yes | 44 | 320 | 4,224 | — | — | ND | ND | Yes | Culture |
ACTA3170 | Male | Yes | 19 | 43,496 | 10,184 | 596 | — | ND | ND | Yes | Culture |
ACTA3171 | Male | No | 28 | 521,920 | 43,200 | 109 | 5 | ND | ND | Yes | Culture |
ACTA3172 | Female | Yes | 48 | 11,072 | 1,672 | — | — | ND | ND | Yes | Culture |
ACTA3173 | Male | Yes | 2 | 57,512 | 11,312 | 6 | 1 | ND | ND | Yes | Culture |
ACTA3174 | Male | Yes | 174 | 400 | 320 | 1 | — | ND | ND | Yes | Culture |
ACTA3175 | Female | Yes | 6 | 45,670 | 43,583 | 93 | 4 | ND | ND | Yes | Culture |
ACTA3176 | Male | Yes | 255 | 320 | 320 | — | — | ND | ND | Yes | Culture |
ACTA3177 | Male | Yes | 294 | 460 | 320 | 3 | — | ND | ND | Yes | Culture |
ACTA3178 | Female | No | 40 | 22,410 | 4,387 | 63 | 15 | ND | ND | Yes | Culture |
ACTA3179 | Female | No | 31 | 31,612 | 27,492 | 1,245 | 589 | ND | ND | Yes | Culture |
ACTA3180 | Female | Yes | 154 | 320 | 320 | — | — | ND | ND | Yes | Culture |
ACTA3181 | Male | Yes | 189 | 356 | 2,563 | 19 | 64 | ND | ND | Yes | Culture |
ACTA3182 | Female | No | 2 | 2,198 | 854 | 496 | 693 | ND | ND | Yes | Culture |
ACTA3183 | Male | Yes | 72 | 7,146 | 1,656 | 526 | 49 | ND | ND | Yes | Culture |
ACTA3184 | Female | Yes | 85 | 320 | 320 | — | — | ND | ND | Yes | Culture |
ACTA3185 | Male | No | 26 | 79,432 | 12,495 | 787 | 6,416 | ND | ND | Yes | Culture |
ACTA3186 | Male | Yes | 5 | 356 | 320 | 35 | 3 | ND | ND | Yes | Culture |
ACTA, Advancing Cryptococcal meningitis Treatment for Africa; CM, cryptococcal meningitis; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; ND, not done; SGA, single-genome amplification.